CASI Pharma Revenue, Profits - CASI Quarterly Income Statement

Add to My Stocks
$5.74 $0.11 (1.95%) CASI stock closing price Sep 18, 2018 (Closing)

Financial analysis of CASI Pharma involves more than just checking the CASI Pharma stock price, by looking at the financial statements of the company in detail. In the income statement, an investor can check for important parameters like the topline or sales, the bottomline or profits, the basic EPS, dividends etc. The income statement is always for an accounting period, typically for a year or quarter, and affects the stock. In this case, the CASI stock is bound to reflect the impact of the QOQ decline of 0. The operating expenses as shown in the CASI Pharma profit and loss statement for 2018 Q2 total to $5.77M. This line item shows that the operating expenses has increased compared with last year. Also check: CASI Pharma assets and CASI Pharma free cash flow.

View and download details of revenue and profits for CASI Pharma for latest & last 40 quarters.
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
CASI Pharma Revenues or Net Sales
Cost Of Goods Sold (COGS)----------
CASI Pharma Gross Profit
Research & Development Expense1.73M2.38M3.86M-1.72M1.04M1.26M1.01M1.36M1.01M
Selling General & Admin Expense4.04M1.3M1.2M---1.43M-1.91M-
Income Before Depreciation Depletion Amortization-5.77M-3.68M-5.06M-1.59M-2.41M-1.69M-2.68M-1.69M-3.27M-1.78M
Depreciation Depletion Amortization----------
Non Operating Income-0.1M--0.01M-0.01M--0.01M-0.01M---
Interest Expense-0.01M---------
CASI Pharma Pretax Income
Provision for Income Taxes----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-5.86M-3.59M-5.05M-1.61M-2.41M-1.7M-2.67M-1.69M-3.29M-1.79M
Extraordinary Items & Discontinued Operations----------
CASI Pharma Profit/ Loss (Net Income)
Average Shares used to compute Diluted EPS86.03M71.22M65.42M60.2M60.2M60.2M58.8M49.23M42.91M40.21M
Average Shares used to compute Basic EPS86.03M71.22M65.42M60.2M60.2M60.2M58.8M49.23M42.91M40.21M
Income Before Nonrecurring Items-5.86M-3.59M-5.05M-1.61M-2.41M-1.7M-2.67M-1.69M-3.29M-1.79M
Income from Nonrecurring Items----------
CASI Pharma Earnings Per Share Basic Net
CASI Pharma Earnings Per Share Diluted Net
EPS Diluted Before Nonrecurring Items-0.07-0.05-0.08-0.03-0.04-0.03-0.05-0.03-0.08-0.04
Preferred Dividends Acc Pd----------
Dividends Common0.000.000.00-------
Dividend Per Share Common0.
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

CASI Pharma stock analysis involves checking at least a few of the important things like:

  • Top line: The word topline comes from the fact that the first line of an income statement refers to sales numbers. If you check you will find that CASI stock has a topline or revenue of $- for 2018 Q2 as per this CASI Pharma revenue chart. Investors look for stocks with a growing top line.
  • Bottom line: The word bottom line comes because it is usually the last line of the income statement and refers to the actual profits after deducting all expenses from the revenues. CASI stock had a poor bottom line growth.

The income statement is also called the profit and loss statement. Apart from the CASI income statement, one can check the CASI Pharma historical stock prices to check how the price has moved with time.

CASI Pharma Income Statement - Key Financial Ratios

Operating Margin
Net Profit Margin